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Introduction: Early diagnosis of intensive care unit – acquired weakness (ICU-AW) using the current reference
standard, that is, assessment of muscle strength, is often hampered due to impaired consciousness. Biological
markers could solve this problem but have been scarcely investigated. We hypothesized that plasma levels of
neurofilaments are elevated in ICU-AW and can diagnose ICU-AW before muscle strength assessment is possible.
Methods: For this prospective observational cohort study, neurofilament levels were measured using ELISA
(NfHSMI35 antibody) in daily plasma samples (index test). When patients were awake and attentive, ICU-AW was
diagnosed using the Medical Research Council scale (reference standard). Differences and discriminative power
(using the area under the receiver operating characteristic curve; AUC) of highest and cumulative (calculated using
the area under the neurofilament curve) neurofilament levels were investigated in relation to the moment of
muscle strength assessment for each patient.
Results: Both the index test and reference standard were available for 77 ICU patients. A total of 18 patients
(23%) fulfilled the clinical criteria for ICU-AW. Peak neurofilament levels were higher in patients with ICU-AW
and had good discriminative power (AUC: 0.85; 95% CI: 0.72 to 0.97). However, neurofilament levels did not peak
before muscle strength assessment was possible. Highest or cumulative neurofilament levels measured before
muscle strength assessment could not diagnose ICU-AW (AUC 0.59; 95% CI 0.37 to 0.80 and AUC 0.57; 95% CI 0.32
to 0.81, respectively).
Conclusions: Plasma neurofilament levels are raised in ICU-AW and may serve as a biological marker for ICU-AW.
However, our study suggests that an early diagnosis of ICU-AW, before muscle strength assessment, is not possible
using neurofilament levels in plasma.Introduction
Intensive Care Unit–acquired weakness (ICU-AW) is a
frequent neuromuscular complication of critical illness
[1]. The disorders causing ICU-AW are critical illness
myopathy (CIM), critical illness polyneuropathy (CIP) or
critical illness neuromyopathy (CINM) [2]. ICU-AW has
important implications for critically ill patients because
mortality and (long-term) morbidity are increased in* Correspondence: L.Wieske@amc.uva.nl
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reproduction in any medium, provided the orICU-AW [1]. The current standard for diagnosing ICU-
AW is muscle strength assessment, quantified using the
Medical Research Council (MRC) scale [2]. In critically ill
patients, muscle strength assessment is frequently delayed
because of impaired consciousness or attentiveness, due
to sedation or delirium [3]. It is important to diagnose
ICU-AW early after onset of critical illness to initiate
supportive interventions, such as early rehabilitation,
which may improve functional outcome [4]. Additionally,
it is important to provide accurate prognostic information
to patients, their families and physicians.
Biomarkers for ICU-AW may facilitate an early diagnosis.
So far, biomarkers of ICU-AW have been scarcely investi-
gated. Creatine kinase, a marker for muscle damage, isLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[2]. Neurofilaments are a biomarker for axonal injury and,
in recent years, have been investigated in various neuro-
logical conditions, such as Guillain-Barré syndrome [5].
CINM and CIP both cause axonal injury and neurofila-
ments might, therefore, be a biomarker for ICU-AW [2].
The purpose of this study was to investigate the diag-
nostic accuracy of neurofilament levels in plasma as an
early marker for ICU-AW. We hypothesized that: 1)
plasma levels of neurofilaments are elevated in patients
with ICU-AW; and 2) plasma levels of neurofilaments
can diagnosis ICU-AW early, before muscle strength
assessment is possible.
Methods
Design and ethical approval
We conducted a prospective observational cohort study
in the mixed medical-surgical ICU of the Academic
Medical Center, Amsterdam, the Netherlands. This
manuscript was drafted in accordance with the Standards
for the Reporting of Diagnostic accuracy studies STARD
criteria [6]. The Institutional Review Board approved the
study (10/219 # 10.17.1630) and waived the need for in-
formed consent, because leftover plasma of blood samples
obtained for routine care was used for this study.
Inclusion and exclusion criteria
Newly admitted ICU patients were eligible for inclusion
in this study, except patients who were admitted because
of stroke, traumatic brain or spinal injury, a neuromuscu-
lar disorder or an infection of the central nervous system.
In addition, we excluded patients after cardiac arrest
and patients who were admitted for post–operative ob-
servation after elective surgery or emergency cardiothor-
acic surgery. Finally, we excluded patients with a poor
pre-hospital functional status (modified Rankin >3 [7])
and patients with pre-existing spinal injury or neurode-
generative disorders.
Medical Research Council scale for muscle strength
(reference standard)
Physical therapists performed manual muscle strength test-
ing as soon as patients were awake (defined as Richmond
Sedation and Agitation Scale (RASS) between −1 (‘drowsy’)
and 1 (‘restless’)) and attentive (able to adequately respond
to verbal commands with arms or eyelids). This was done
as part of routine care. Factors precluding strength assess-
ment, such as delirium or sedation, were also noted.
Muscle strength examination using the MRC scale has
good intra- and inter-observer variability, when employed
in awake and attentive patients [3,8,9]. Muscle strength
was assessed in a protocolized way using the MRC scale
and scored as an integer. The following muscle groups
were tested bilaterally: shoulder abductors, elbow flexors,wrist flexors, hip flexors, knee extensors and ankle dorsi-
flexors. The assessment was done without knowing
neurofilament results. Individual muscle scores were
summated and divided by the number of muscles tested
to obtain an average MRC score. ICU-AW was defined
as an average MRC-score <4 [2].
Collection of samples and measurement of neurofilaments
(index test)
For every day of ICU admission, samples were collected
from leftover ethylenediaminetetraacetic acid (EDTA)
plasma used for routine care. Plasma was aliquoted
with a sampling code blinded for study outcome and
stored at −80°C within four hours after they were obtained
from patients.
Neurofilament levels were measured using a previously
described ELISA [5,10]. After all samples had been
collected, analyses were done batch-wise, to minimize
differences in standard preparation and buffers [11].
Samples containing less than 100 μl were measured
once; all other samples were measured in duplicate.
As a capture antibody we used NfHSMI35 (SMI-35R;
Covance Inc, Princeton NJ, USA), which binds various
phosphorylated forms of the heavy-chain neurofilament
protein [5]. The median analytical error (coefficient of
variation; CV) was 7.9% (interquartile range (IQR): 3.7 to
14.0). For samples with CV values >30%, the ELISA was
repeated, if sufficient plasma was still available. Samples
with CV values >30% at re-measurement or samples that
could not be re-measured were excluded from the ana-
lysis. For samples with neurofilament levels <1 ng/ml a
CV >30% was accepted. The detection limit in this study
was 0.026 ng/ml. For samples with a neurofilament level
below the detection limit we imputed the neurofilament
level at half the detection limit (that is, 0.013 ng/ml).
Sample analysis and selection was performed blinded to
study outcome.
Clinical data collection
The following clinical characteristics were collected: age,
gender, admission type, presence of sepsis, severe sepsis
and septic shock during admission (definitions according to
[12] and [13], respectively), Acute Physiology and Chronic
Health Evaluation IV (APACHE IV) score, presence of
multiple organ dysfunction syndrome (MODS) during
admission (defined as organ failure (organ specific
Sequential Organ Failure Assessment (SOFA) score >2) in
two or more organ-systems occurring on the same day
[14]) and presence of central nervous system (CNS)
organ failure during admission (defined as CNS SOFA
score >2 on any day during admission). In addition, data
on neurological co-morbidities were collected: presence of
risk factors for polyneuropathy (such as diabetes mellitus,
alcohol abuse, renal insufficiency or chemotherapy),
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CNS disorders in the medical history (such as stroke or
epilepsy).
Statistical analysis
Depending on the distribution, data are presented as mean
values with standard deviation (± SD), as median values
with IQR or as proportions with percentages and total
numbers. Differences between proportions were assessed
using Fisher’s exact test. Differences between normally
distributed variables were assessed using Welch’s t-test;
differences between non-normally distributed continuous
variables were assessed using the Wilcoxon rank-sum test.
To investigate if neurofilament levels are elevated in
ICU-AW, we assessed differences in neurofilament peak
levels occurring any time during admission. Discriminative
power was analyzed by constructing receiver operating
characteristic (ROC) curves. From ROC curves, the area
under the curve (AUC) with 95% confidence interval (CI)
was calculated. We defined discriminative power of AUC
values between 0.90 to 1 as excellent, between 0.80 to 0.90
as good, between 0.70 to 0.80 as fair, between 0.60 to 0.70
as poor and <0.60 as failed. The optimal cut-off point
of the ROC curve was defined as the point with maximal
distance from the diagonal reference line and the sensitiv-
ity and specificity of that cut-off point were calculated.
Differences between the day of neurofilament peak levels
and day of muscle strength assessment were analyzed
using the paired samples Wilcoxon signed-rank test.
We also investigated if neurofilaments could diagnose
ICU-AW early, that is, before muscle strength assessment
was possible. To adjust for the differences in ICU length
of stay, we investigated this in a cohort of equal observa-
tion length. To define ‘early’ we chose the day before
which, in 50% of the patients, muscle strength could have
been assessed. Patients in whom strength could not be
assessed before this day were used in this analysis. Samples
from this group obtained before this 50th percentile day
were used to analyze differences in, and discriminative
power of, the highest and cumulative neurofilament levels.
Cumulative levels were calculated using the area under
the neurofilament curve of individual patients.
Finally, we investigated the influences of chronic neuro-
logical co-morbidities on admission and peak neurofila-
ment levels occurring at any time during admission.
Admission neurofilament levels were defined as samples
from ICU day 0 or 1. Also, we investigated the influence
of concomitant critical illness-induced CNS organ failure
on peak neurofilament levels occurring any time during
admission.
Statistical significance is defined as P ≤0.05. Analyses
were done using R (version: 2.15.2; R Foundation for
Statistical Computing, Vienna, Austria). ROC analyses were
done using the pROC package [15]. This cohort study wasan observational exploratory study and in view of the
explorative nature of this study the sample size was
chosen on pragmatic grounds. Moreover, no previous
data on plasma neurofilament levels in patients with
ICU-AW exist, making it impossible to perform a reliable
power calculation.
Results
Between November 2011 and May 2012, a total of 108
patients were included in the study (Figure 1). In 77 patients
both muscle strength assessment (reference standard) and
results from the neurofilament ELISA (index test) were
available. Unless otherwise specified, this population was
used for analysis. Patient characteristics are displayed in
Table 1. From these 77 patients, 618 plasma samples were
collected over time. The ELISA was successfully performed
in 583 of 618 (94%) samples; reasons for unsuccessful ELISA
were a CV of >30% in 13 samples and not enough plasma
in 22 samples. A total of 534 of 583 (92%) samples were
measured in duplicate; the remainder were measured once.
Neurofilaments levels in ICU-AW
Figure 2A shows neurofilament levels in all plasma samples
for patients with and without ICU-AW. Additional file 1:
Figure S1 shows plasma levels of patients in whom muscle
strength assessment was not possible. Peak neurofilament
levels occurring at any time during ICU admission were
higher for patients with ICU-AW (Figure 2B). Discrimina-
tive power of peak neurofilament levels was good as shown
in Figure 3A. The optimal cut-off was 17.9 ng/ml (sensi-
tivity: 83% and specificity: 81%). Neurofilament levels of
patients with ICU-AW peaked at ICU day 7 (median, IQR:
5 to 14). This was not significantly earlier than the moment
of muscle strength assessment (Table 1; P 0.96). Figure 4
shows a longitudinal profile of neurofilament levels.
Early diagnosis of ICU-AW before muscle strength
assessment
Before ICU day 5, 50% of all patients could be assessed
for muscle strength. This yielded a total of 38 patients
for the subgroup analysis of early diagnosis (15 with ICU-
AW and 23 patients without ICU-AW). In this group,
highest neurofilament levels until ICU day 5 did not differ
between ICU-AW or no ICU-AW (median: 10.7 ng/ml
(IQR: 7.2 to 20.6) versus 11.7 ng/ml (IQR: 10.5 to 13.5);
P 0.37), nor did the cumulative levels until ICU day 5
(median: 26.9 ng/ml (IQR: 16.6 to 41.5) versus 28.8 ng/
ml (IQR: 25.5 to 37.0) ICU-AW; P 0.61). Discriminative
power was not significant (Figure 3B and C).
Influences of concomitant CNS organ failure and chronic
neurological co-morbidities on neurofilament levels
In Figure 5 peak neurofilament levels occurring at any
time during ICU admission are shown for patients with
Figure 1 Flow chart describing enrollment of patients. CAPU, cardiopulmonary surgery; CNS, central nervous system; CPR, cardiopulmonary
resuscitation; ICU-AW, Intensive Care Unit–acquired weakness; MRC, muscle strength as assessed with the Medical Research Council scale; NMD,
neuromuscular disorder.
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failure. Higher peak neurofilament levels were observed in
patients with ICU-AW when compared to patients without
ICU-AW, both when CNS organ failure was not present
(P <0.01) and when CNS organ failure was present (P 0.05).
Admission neurofilament levels were not different for pa-
tients with any of the chronic neurological co-morbidities
(Additional file 2: Figure S2a). Peak neurofilament levels ob-
served at any time during admission were higher for patients
with a pre-existing polyneuropathy compared to patientswithout a pre-existing polyneuropathy; no differences in
peak levels were observed for any of the other chronic
neurological co-morbidities (Additional file 2: Figure S2b).
Discussion
This study shows that neurofilament levels are elevated
in patients with ICU-AW compared to patients without
ICU-AW. Peak neurofilament levels have good discrimina-
tive power, but peak levels were not observed prior to the
moment of muscle strength assessment. Neurofilament
Table 1 Patient characteristics
ICU-AW (N:18) no ICU-AW (N:59) P-values
Demographics
Men, number (%) 10 (56) 38 (64) 0.58
Age, mean year ± SD 64 ± 15 60 ± 15 0.25
Neurological co-morbidities
Risk factors for polyneuropathy, number (%) 8 (44) 28 (47) 1
Pre-existing polyneuropathy, number (%) 2 (11) 2 (3) 0.23
History of CNS disorder, number (%) 3 (17) 5 (8) 0.38
Any neurological co-morbidity, number (%)a 12 (67) 34 (57) 0.59
Admission characteristics
Admission type
Medical, number (%) 12 (67) 45 (76) 0.54
Surgical, number (%) 6 (33) 14 (24)
LOS ICU, median days (IQR) 15 (6 to 34) 3 (1 to 6) <0.01
APACHE IV score, mean ± SD 85 ± 25 68 ± 22 0.02
Sepsis during admission, number (%) 18 (100) 45 (76) 0.03
Severe sepsis during admission, number (%) 17 (94) 30 (51) <0.01
Septic shock during admission, number (%) 14 (78) 15 (25) <0.01
MODS during admission, number (%) 16 (89) 30 (51) 0.01
CNS organ failure during admission, number (%) 8 (44) 4 (7) <0.01
Moment of muscle strength assessment, median day (IQR) 8 (5 to 14) 4 (2 to 6) <0.01
Average MRC score, median (IQR) 2.8 (1.7 to 3.6) 4.8 (4.2 to 5)
aPresence of at least one of the individual neurological co-morbidities within a patient. APACHE IV, Acute Physiology and Chronic Health Evaluation IV score; CNS, central
nervous system; ICU-AW, Intensive Care Unit–acquired weakness; LOS ICU, length of stay in the intensive care unit; MODS, Multiple Organ Dysfunction syndrome.
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assessment. This suggests that neurofilaments are not
useful as an early diagnostic marker for ICU-AW.
Neurofilaments as an early marker for ICU-AW
Our study is the first to measure neurofilaments in plasma
as a biological marker for ICU-AW. Neurofilaments
are markers of structural damage to axons, and raisedFigure 2 Neurofilaments in patients with and without Intensive Care
(A) and peak (B) neurofilament levels per patients. Horizontal bars show m
MRC, Medical Research Council; NfH, neurofilaments.neurofilaments in patients with ICU-AW would suggest
structural damage to peripheral nerves. In contrast to
our hypothesis, neurofilaments did not allow for an
early diagnosis of ICU-AW, because neurofilament levels
did not peak before muscle strength assessment was pos-
sible. This supports the theory that in ICU-AW, structural
damage of peripheral nerves develops after a period of
dysfunction. Therefore, damage is a late event [16]. OurUnit-acquired weakness. Neurofilament levels in all plasma samples
edian group values. ICU-AW, Intensive Care Unit–acquired weakness;
AUC:0.85 95%CI: 0.72 to 0.97 (N:59/18)
optimal cut−off
AUC:0.59 95%CI: 0.37 to 0.80 (N:23/15) AUC:0.57 95%CI: 0.32 to 0.81 (N:14/11)

















Figure 3 Neurofilament receiver operating characteristic curves for Intensive Care Unit–acquired weakness. Overview of discriminative
power of different neurofilament measures. A) displays peak neurofilament levels at any time during admission. B) displays the highest neurofilament
level and C) cumulative neurofilament level before muscle strength assessment was possible, in a diagnostically relevant cohort of patients (see text for
explanation). The number of patients analyzed per curve is denoted as N: number of patients without ICU-AW/number of patients with ICU-AW. Some
additional patients are excluded in C) when compared to B), because both admission and ICU day 4 samples needed to be present to calculate
cumulative neurofilament levels (that is, area under the neurofilament curve). AUC, area under the receiver operating characteristic curve; MRC, Medical
Research Council; NfH, neurofilaments.
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earlier than reported in previous studies, which found
histopathological signs of structural damage only weeks
after the onset of critical illness [16].
Other etiologies for raised neurofilaments in critically
ill patients
Neurofilaments are non-specific markers for axonal
injury. They have been identified as possible markers,
either in blood or cerebrospinal fluid, for several per-
ipheral and central neurological disorders, such as
Guillain-Barré syndrome, stroke, multiple sclerosis,
amyotrophic lateral sclerosis, spinal cord injury and
post-anoxic coma [5,17-21]. Therefore, raised neurofil-
ament levels in patients with ICU-AW may also have
another origin. Concomitant critical illness-induced
CNS injury may contribute to systemic neurofilament
levels. Critical illness can induce axonal damage in the
CNS [22]. ICU-AW and CNS organ failure are both
manifestations of MODS and will frequently co-occur
in patients [23,24]. In our study we found two patients
with serious CNS organ failure and exceptionally high
neurofilament levels. We did not find differences in
peak neurofilament levels for patients with or without
CNS organ failure when compared to patients with or
without ICU-AW. However, this may be caused by
small subgroup sizes.
Another source for systemic neurofilament levels may
be pre-existing neurological disorders [21]. Except for
patients with a pre-existing polyneuropathy, we did
not find differences in neurofilament peak or admission
levels for any of the chronic neurological co-morbidities.Longitudinal neurofilament profiles suggest different
patterns for patients with and without chronic neuro-
logical co-morbidities. However, group sizes were too
small and heterogeneous to draw a reliable conclusion.
Other modalities for an early diagnosis of ICU-AW
Other diagnostic modalities may also be valuable to estab-
lish an early diagnosis of ICU-AW. Early measurement
of muscle excitability using direct muscle stimulation, a
specialized form of electrophysiological studies, has
been found to reliably predict development of ICU-AW
[25]. The technique of direct muscle stimulation is not
widely available and electrophysiological studies in general
are difficult to perform in the ICU setting because of
technical limitations, such as limb edema or electrical
interference. Another promising diagnostic modality is
early muscle ultrasound [26]. Sensitivity and specificity
for prediction of a clinical diagnosis of ICU-AW are not
yet known.
Limitations
In this first exploratory study, we used the current refer-
ence standard to diagnose ICU-AW, as proposed by inter-
national guidelines [2]. Muscle strength assessment cannot
discriminate between CINM, CIP and CIM as the under-
lying disorder for ICU-AW [2]. Although CINM is thought
to be most prevalent, we cannot exclude the possibility that
some of our patients, in fact, had isolated CIM as the
underlying disorder causing ICU-AW [2].
Second, our study design may have led to information
bias. Patients without ICU-AW had a shorter ICU stay





































































Figure 4 Profile of plasma neurofilament levels in patients with and without Intensive Care Unit-acquired weakness. Longitudinal
neurofilament profiles, represented as changes compared to baseline levels, over a 10 day period following admission to ICU. Light gray lines represent
individual patients; the black lines summarize group levels using local fit regression lines (with the 95% confidence curves in the grey shaded area). In
patients without ICU-AW, neurofilament levels remained relatively stable on a group level (A), regardless of the presence of chronic neurological
co-morbidities (C and E). In patients with ICU-AW there was a rise over time (B). ICU-AW patients without any chronic neurological co-morbidity had a
more homogenous neurofilament profile (D) when compared to patients with any chronic neurological co-morbidity (F). Data are missing for seven
patients because admission blood samples were not obtained or could not be analyzed successfully. ICU-AW, Intensive Care Unit–acquired weakness;
NfH, neurofilaments.
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have led to an overestimation of the observed differences.
For our analysis of neurofilaments as an early diagnostic
marker, we corrected for this possible bias by selecting a
cohort of equal observation length.
Third, because we were unable to perform a reliable
power analysis, there is a risk that our study is under-
powered. Finally, we only investigated neurofilaments
recognized by the NfHSMI35 antibody. NfHSMI35 has the
best technical characteristics of all neurofilament heavy
chain antibodies, but it does not bind to all different
phosphorylated forms [5]. In axonal injury, different
degrees of phosphorylation have been described and
other neurofilament heavy chain phosphoforms or a com-
bination with other neurofilament isoforms, such as the
light chain, might provide better diagnostic accuracy in
ICU-AW [17].Recommendations for future studies
Although probably not suitable as an early marker for
ICU-AW, other possible applications of neurofilaments
as a biological marker for ICU-AW warrant future studies.
Raised neurofilaments may aid in solving differential diag-
nostic difficulties when differentiating between CIM, CIP
or CINM, which is currently dependent on technically
challenging electrophysiological studies and/or invasive
muscle biopsies [2]. Additionally, raised neurofilaments
could have prognostic consequences. Both axonal damage
instead of dysfunction and axonal involvement instead of
muscle involvement are associated with adverse outcomes
in patients with ICU-AW [16,27,28]. However, two tech-
nical issues remain to be solved before launching new
studies. Firstly, intra-laboratory CV for the neurofilament
heavy chain ELISA needs to be investigated, because this
was shown to be poor for neurofilament light chain ELISA
Figure 5 Peak neurofilament levels and concomitant central nervous system organ failure. Peak neurofilaments for patients with and
without Intensive Care Unit–acquired weakness (ICU-AW) and with and without central nervous system (CNS) failure. Horizontal black bars show
median group values. Overall test for differences between groups (that is, Kruskal-Wallis), P <0.01; because of the exploratory nature there was no
adjustment for multiple comparisons. CNS, central nervous system; ICU-AW, Intensive Care Unit–acquired weakness; NfH, neurofilaments.
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study should be interpreted with caution when imple-
mented in other laboratories. Secondly, the reliability of
the assay within the ICU environment needs to be investi-
gated because there may be interference by blood-borne
factors, such as ICU-specific medication, or by changes in
plasma levels not related to axonal injury, such as dilution
because of fluid resuscitation or accumulation because of
decreased clearance.
Conclusions
Clinically, there is a need for alternative diagnostic ap-
proaches that allow for early diagnosis of ICU-AW.
The current approach, using manual muscle strength
assessment, is frequently delayed and important prognos-
tic information is thus withheld. While plasma neurofila-
ment levels are raised in ICU-AW, the time at which
these levels peak precludes the use of this neurofilament
assay as an early diagnostic marker for ICU-AW.
Key messages
 Plasma neurofilament levels, a biomarker for axonal
damage, are raised in patients with Intensive Care
Unit–acquired weakness.
 An early diagnosis of Intensive Care Unit–acquired
weakness before muscle strength assessment is
probably not possible using plasma neurofilament
levels.Additional files
Additional file 1: Figure S1. Neurofilaments in patients with and
without Intensive Care Unit-acquired weakness and in patients without
muscle strength assessment. Neurofilament levels in all plasma samples
(A) and peak (B) neurofilament levels per patients. Horizontal bars show
median group values. In the no MRC group, we identified two patients with
higher neurofilament levels than others. One of those patients suffered from
coma due to a hepatic encephalopathy (samples denoted with +), while the
other patient had prolonged delirium (samples denoted with a white
square).
Additional file 2: Figure S2. A) Admission neurofilament levels for
chronic neurological co-morbidities. Admission neurofilament levels
(ICU day 0 or 1) for patients with and without chronic neurological
co-morbidities. Horizontal black bars show median group values. Data are
missing for seven patients because admission blood samples were not
obtained or could not be successfully analyzed. B) Peak neurofilament
levels for chronic neurological co-morbidities. Peak neurofilament levels
for patients with and without chronic neurological co-morbidities.
Horizontal black bars show median group values.
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